Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in CMML and Atypical CML
NCT00079313Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jan 2004
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in chronic myelomonocytic leukemia (CMML), Atypical chronic myeloid leukemia (aCML), sponsored by National Heart, Lung, and Blood Institute. Started Jan 2004; status: completed.
02
Drugs
03
Conditions
chronic myelomonocytic leukemia (CMML)Atypical chronic myeloid leukemia (aCML)
Beyond the preview
Go deeper on NCT00079313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00079313.